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Abstract: Pharmacist prescribing is being increasingly undertaken to better use their skills and 
reduce the workload of existing prescribers such as doctors, often using formal processes to 
legitimate these activities. In developing countries like Saudi Arabia, however, pharmacists’ 
prescribing remains informal with no legislation or formal training and there is a lack of research 
and understanding into such practices. Therefore, we aimed to describe current pharmacist 
prescribing practices in Saudi Arabia and explore pharmacists’ views about pharmacists’ 
prescribing. This is a cross-sectional survey study using an online questionnaire of hospital 
pharmacists in Saudi Arabia about pharmacists’ prescribing, and associated views about 
prescribing legislation and barriers to implementing pharmacist prescribing. Over a quarter 
(28.5%) of pharmacists reported themselves as prescribers, 49% were following a collaborative 
prescribing model, 18% independent prescribing, and 33% were doing both. Ninety percent of 
prescribers reported confidence in prescribing the appropriate treatment and 92.3% perceived they 
will benefit from more prescribing training. Healthcare practice culture and pharmacist’s 
competency were identified as barriers. There is an overall support for pharmacists’ prescribing in 
Saudi Arabia among this sample of hospital pharmacists, with limitations in resources and the 
absence of standardized prescribing training being perceived as key barriers to pharmacists’ 
prescribing. 
Keywords: Saudi Arabia; pharmacist prescribing; attitude; prescribing model; questionnaire 
 
1. Introduction 
Over the past few decades, the role of the pharmacist in many countries has evolved from being 
a compounder and a supplier of medicines, toward a patient-care provider. This involves a range of 
new responsibilities that includes complex medication management, screening for chronic disease, 
educating patients, transition of care, drug prescribing, and health promotion activities [1–3]. Early 
involvement of pharmacists in the prescribing process by granting them the right to prescribe can 
help in optimizing medication use [4]. The practice of non-medical prescribing (NMP) emerged to 
meet patients’ needs in terms of timely and convenient access to prescribed drugs [5]. As the name 
suggests, NMP is undertaken by healthcare professionals from non-medical backgrounds such as 
nurses, pharmacists, and other allied healthcare professionals who, after receiving training in 
prescribing are granted the legal authority to prescribe medications [6]. The recognition of 
pharmacists in developed countries as an underutilized healthcare group was a driver to this change 
Pharmacy 2020, 8, 160 2 of 18 
 
in prescriptive authority [5,7]. At the forefront of these NMP changes were the United Kingdom 
(UK), the United States of America (USA) and Canada, where nurses at first were allowed to 
perform prescribing activities in both hospital settings and ambulatory care clinics [8]. However, 
there are different prescribing models practiced by pharmacists internationally and with different 
degrees of independence [4]. Independent prescribing (IP) models involve a healthcare practitioner 
being solely responsible for diagnosing and assessing patients’ medical condition and any associated 
medicine prescribing [9]. Supplementary prescribing (SP) involves a voluntary partnership between 
an IP (often a doctor) and a supplementary prescriber, using a patient-centered clinical management 
plan (CMP) agreed by the physician [4]. There is also collaborative prescribing (CP), which is similar 
to the SP model and practiced mainly in the USA and Canada. CP requires a cooperative 
relationship between physicians and pharmacists that gives pharmacists the authority to prescribe 
[4]. 
Earlier research on pharmacists’ prescribing has explored the perspectives of pharmacists on 
adopting a prescribing role and how it affects their professional responsibility. A systematic review 
of stakeholders’ views and experiences of pharmacist prescribing that included 65 studies from 
limited number of countries reported that the main drivers to pharmacists adopting a prescribing 
role were better patient management, improving self and professional confidence, developing a 
clinical role, reducing therapy costs and patient satisfaction [10]. Moreover, many international 
studies have reported pharmacist prescribing benefits relating to improved patients’ outcomes, 
reduced physician workload, more accessibility to healthcare services, better utilizations of 
pharmacist’s skills, and improved job satisfaction [10]. A thematic review of literature relating to SP 
in the UK reported that nurse and pharmacist practitioners were generally confident about SP and 
that it has been well implemented in different clinical settings in the UK [11]. The review also found 
that time, funding, and primary care strategy were significant barriers to the implementation of SP. 
Evidence from hospital pharmacists in the USA suggested that the absence of support from 
physicians and other medical staff were key barriers, while support from senior administrators and 
physicians, along with pharmacists’ training and their willingness to participate in collaborative 
drug-therapy management were important facilitators [12]. Previous studies have also reported that 
pharmacists face difficulties in making prescribing decisions, which reflects the limitations in 
pharmacists training and education that could also represent a barrier to any pharmacist prescribing 
model [13,14]. 
In the Kingdom of Saudi Arabia (KSA), pharmacy practice has evolved dramatically over the 
past 30 years, with currently 28 pharmacy schools granting bachelor’s in pharmacy (BSc.Pharm) or 
Doctor of Pharmacy (PharmD) degree, and the establishment of postgraduate residency training 
programs [15]. Although, there is still inconsistency in the names of pharmacy baccalaureate 
programs or degree names in KSA, such as “Pharmacy”, “Clinical Pharmacy”, “PharmD” and 
“BSc.Pharm”, with an increase in pharmacy schools offering PharmD degree, all these programs 
qualify graduates to practice as pharmacists in KSA [16,17]. In the community setting, the role of 
pharmacists in KSA is limited to dispensing medications and counseling patients, and traditionally 
in hospitals, pharmacists in KSA have been involved in verifying prescriptions, dispensing, 
management of stored medications and pharmaceutical supplies [15]. Clinical pharmacy practice in 
KSA is relatively well established mainly at tertiary care hospitals and is underpinned by 
pharmaceutical care principles that originated in the US [18]. The majority of clinical pharmacists in 
KSA have completed postgraduate residency training (i.e., postgraduate year one, PGY1) or 
specialized training (PGY2) either in national or overseas training programs. On an institutional 
level, clinical pharmacists in KSA are involved in running clinics for anticoagulation, cardiology and 
ambulatory care, and practice within a collaborative agreement with physicians that allow 
pharmacists to prescribe medications and order laboratory tests within the terms and conditions of 
the agreement. Pharmacists with prescriptive authority are usually experienced clinical pharmacists 
who have complete postgraduate training (PGY1 and/or PGY2) [15]. However, these activities are 
currently still considered informal forms of prescribing as there is no national legislation that 
supports any official prescribing by pharmacists. For this reason, and due to the scarcity of research 
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that addresses the role of pharmacists as prescribers in KSA, this study aimed to provide 
quantitative evidence of the current practice of pharmacists’ prescribing in KSA and explore their 
perspectives for further extending the role of pharmacists to prescribers. 
2. Materials and Methods 
2.1. Study Design 
This study utilized a cross-sectional descriptive design, in which an electronic survey was 
developed and used to collect quantitative data about Saudi pharmacists’ prescribing activities and 
explore their attitude on current practice and their willingness to practice as prescribers. The study 
was approved by the research ethics committee at the School of Health and Related Research, 
University of Sheffield, UK (application number: 025528). 
2.2. Sampling 
The study started from the 1st of July 2019 and survey dissemination continued for 8 weeks 
until the 31st of August 2019. The target population was registered hospital pharmacists in KSA; 
pharmacists working only in retail pharmacies or non-hospital setting were excluded from the 
study. Licensed pharmacists working in hospital settings of 300 bed capacity or more were invited to 
participate in this study. The study was conducted at hospitals located in different regions in KSA 
(e.g., Makkah, Riyadh, Eastern province, Qassim, Madinah). Twenty-six eligible hospitals were 
identified using the MOH statistics book for the year 2018 [19]. Hospital pharmacists were also 
approached via two professional societies in KSA. The first was the Saudi Society of Clinical 
Pharmacy (SSCP), which is a sub-branch of the Saudi Commission for Health Specialties (SCHS) 
established in 2018, which represents clinical pharmacists in KSA; at the time of conducting this 
study the society had 153 pharmacist members [20]. The second was the Saudi Oncology Pharmacy 
Assembly (SOPA), which is part of the Saudi Oncology Society established in 2018 to support and 
advance oncology pharmacy practice in KSA, and include 60 pharmacist members [20,21]. Sample 
size calculation was done based on the number of pharmacist members in the SSCP and SOPA. Since 
the number of employed pharmacists at each of the 26 eligible hospitals was not disclosed to the 
investigators until pharmacy directors confirmed their participation, it was assumed that on an 
average 50 pharmacists were employed at each hospital. Using an online sample calculator (Raosoft, 
Inc, Seattle, Washington, USA; http://www.raosoft.com/samplesize.html), with a chosen accepted 
error margin of 5%, a 95% confidence level and a 50% response distribution within the described 
population, the minimum required sample size was 309 participants. 
2.2.1. Questionnaire Development 
An electronic survey was developed using Google forms to collect data from participants. All 
questions included in the survey were developed to collect answers in a complete anonymized form 
to protect anonymity. The survey instrument included 25 questions divided into three sections: the 
first captured demographic details such as participants’ years of practice, qualifications, practice 
settings, and workload (Table 1); the second section assessed participant opinions and perspectives 
on different aspects of pharmacists’ prescribing in KSA; the final section was completed only by 
pharmacists who self-reported undertaking prescribing duties, to explore prescribing models used, 
commonly prescribed medications and views on their prescribing experience. Attitudinal questions 
used a 5-point Likert scale to capture responses to a series of statements. Open-ended questions were 
included to allow participants to elaborate more on the barriers and facilitators for adopting 
pharmacists’ prescribing practice in KSA and add in any additional comments they felt were 
relevant to this topic. All survey items were designed in English, as all pharmacy graduates in KSA 
have received their undergraduate education in English [16]. The developed survey instrument 
went through a pilot process to assess the appropriateness of the survey in collecting the required 
data from pharmacists and the time needed to complete the electronic questionnaire. A pilot stage 
was performed on a group of five licensed pharmacists in KSA, and they were asked to provide 
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feedback on their experience in completing the survey. Pharmacists who took part in the pilot study 
were asked not to participate in the main survey study. 
2.2.2. Data Collection 
Pharmacists were invited to participate in this study via an email that was sent from the SSCP 
and SOPA. In addition, pharmacy directors at eligible hospitals were contacted by e-mail and asked 
to participate by completing the electronic survey and disseminating the survey to pharmacists 
working at their institutions. To mitigate multiple completions of surveys by the same pharmacist, a 
specific note was added at the start of the electronic survey asking participants to complete the 
survey only once. 
2.2.3. Approach to Analysis 
All quantitative data collected from participants were exported from Google forms and 
imported for analysis to Statistical Package for Social Sciences (SPSS) version 25. Descriptive analysis 
of percentages and frequencies was undertaken for the categorical variables. Continuous variables 
were reported as means and standard deviations (SD), while median and interquartile ranges (IQR) 
were reported for variables with skewed distribution. Inferential statistics were carried out using 
Chi-square (χ2) test to explore the possible associations between pharmacists’ prescribing status and 
key independent variables. Independent t-test was also used to determine if there is a difference 
between the average weekly working hours between participants who prescribe and those who do 
not. Furthermore, Fisher’s exact test was used to determine if there is a difference between the two 
groups in variables where the groups were small such as ages, years of practice and monthly 
income. Correlation analysis was undertaken using Spearman’s rank correlation to investigate the 
strength of associations between Likert scaled variables (e.g., awareness of legislation or level of 
confidence of prescribing pharmacists) and ordinal variables (e.g., years of experience and 
qualifications). All responses were handled in a complete case analysis, and to limit the effect of 
missing data, all questions included in the survey tool were required to be filled by respondents, 
except for two questions (i.e., monthly income and the open-ended question on the barriers and 
facilitators of pharmacists’ prescribing). For all the statistical tests that were undertaken, a p value of 
< 0.05 was considered statistically significant. All responses reported in the open-ended questions 
were analyzed separately using the thematic approach proposed by Marshall and Rossman [22]. 
This involved one investigator (AA) reading each open-ended response several times and becoming 
engaged and familiar with the data and being able to reflect on possible themes discussed by 
participants. Then, an inductive coding approach was applied where all codes arise directly from 
participants’ responses. The coding process was performed by AA and completed when no more 
codes could be identified from the data. Then, the identified descriptive themes were evaluated and 
compiled for data analysis. 
3. Results 
3.1. Study Sample and Response Rate 
The survey was disseminated to 153 pharmacist members in SSCP, and 60 pharmacist members 
in SOPA. Out of the 26 eligible institutions contacted and invited to participate in this survey study, 
only 14 hospitals agreed to participate with a total of 712 pharmacists working at these institutions 
who received an invitation to complete the electronic survey. In total, 141 responses were received, 
with 4 being excluded as they were from respondents from retail pharmacies and non-hospital 
setting giving a total of 137 responses and a response rate of 14.8%. 
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3.2. Respondents Characteristics 
Table 1 presents a summary of participant demographic characteristics. Of the 137 pharmacists 
who completed the survey just over half (52.5%, n = 72) were females. Around half of the 
respondents had less than five years of professional experience (47.5%, n = 65) with nearly a quarter 
reporting 6 to 10 years of experience (24%, n = 33). Forty percent of participants (n = 55) held a 
Pharm.D degree as a qualification to practice pharmacy and 19.7% (n = 27) had a BSc.Pharm degree. 
Twenty-three percent of respondents (n = 32) completed pharmacy residency training of which 
13.1% (n = 18) were graduates of PGY1 training programs, and 10.2% (n = 14) completed PGY2 
specialized training programs. The majority of respondents were working at governmental hospitals 
(76.6%, n = 105), and the majority were working at Makkah region (57%, n = 78) followed by Riyadh 
region (19%, n = 26). Just over one third of the respondents were working at clinical pharmacy 
settings (35.9%, n = 49) who are practicing as pharmacy practice resident or as clinical pharmacist or 
as specialized clinical pharmacist. This was followed by respondents working at an outpatient 
pharmacy setting (24%, n = 33). 
Table 1. Pharmacists’ respondent characteristics (n = 137). 
Demographic Variables % (n) 













































Years of practice as a qualified pharmacist 
<5 years 
6 to 10 years 
11 to 15 years 
16 to 20 years 
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Clinical pharmacist 









Monthly income $ 
<SR * 10,000 
SR 10,000–SR 20,000 
SR 20,000–SR 30,000 







$ Responses may not add to 100% because of 4 missing responses. * SR: Saudi Riyal. 
3.3. Perspectives on Pharmacists’ Prescribing 
Just under half of the respondents (47.5%, n = 65) were aware that there is no national legislation 
to support pharmacist prescribing in KSA (Table 2). The majority of respondents (77%, n = 105) 
agreed that there was a need for legislation to support pharmacists’ prescribing in KSA, which was 
not correlated with age or experience (r = 0.177, p = 0.282; r = 0.048, p = 0.770, respectively) but was for 
highest professional/academic qualifications (r = 0.211, p = 0.014). 
However, opinions were more divided regarding the prescribing model favored: (41.6% n = 57) 
agreed that pharmacists should prescribe independently of physicians but more (69.3%, n = 95) 
agreed with a collaborative prescribing model. The majority also felt that prescribing should be 
limited to competent clinical pharmacists (65%, n = 89) and (90.5%, n = 124) agreed that pharmacists 
should receive training specific to the therapeutic areas they will prescribe within (Table 2). There 
was a positive correlation between respondents’ attitude toward pharmacists’ prescribing training 
and highest professional/academic qualifications (r = 0.264, p = 0.002). There was a general 
agreement with all the statements that described the potential benefits of implementing pharmacist 
prescribing. These included increasing patients’ access to medications (82.5%, n = 113) and 
improving the overall quality of care for patients (76.6%, n = 105). Participants expressed less 
agreement with the benefit of reducing prescribing errors (63.5%, n = 87), and with patients avoiding 
physician follow-up (51.8%, n = 71) (Table 2). 
In relation to the impact that prescribing could have for pharmacists, most respondents (89.1%, 
n = 122) agreed that prescribing will increase pharmacist’s professional responsibility. The majority 
(84.7%, n = 116) agreed that prescribing allows utilization of pharmacist’s skills and experience and 
offered more job satisfaction (81%, n = 111). However, 70.1% (n = 96) of respondents acknowledged 
that prescribing would increase pharmacist’s workload (Table 2). 
Table 2. Respondents’ opinions on statements regarding pharmacists’ prescribing (n = 137). 
Statements 
Responses* % (n) 
Strongly 




Score (IQR) * 
There is national legislation that 
support pharmacists’ 
prescribing in KSA 
5.8 (8) 24.8 (34) 21.9 (30) 30.7 (42) 16.8 (23) 3 (2–4) 
Legislation to support 
pharmacist prescribing should 
be available in KSA 
35.1 (48) 41.6 (57) 14.6 (20) 5.8 (8) 2.9 (4) 4 (4–5) 
Pharmacists should be allowed 
to prescribe independently of the 
medical team 
14.6 (20) 27 (37) 23.4 (32) 24 (33) 11 (15) 3 (2–4) 
Pharmacists should only be 
allowed to prescribe in 
collaboration with physicians 
28.5 (39) 40.8 (56) 19 (26) 8.8 (12) 2.9 (4) 4 (3–5) 
Prescribing should be limited to 
competent clinical pharmacists 32.1 (44) 32.8 (45) 16.1 (22) 11 (15) 8 (11) 4 (3–5) 
Pharmacists should be trained in 
specific therapeutic areas before 
61.3 (84) 29.2 (40) 5.1 (7) 2.9 (4) 1.5 (2) 5 (4–5) 
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they are allowed to prescribe 
Pharmacist prescribing will 
allow greater patient access to 
medications 
40.2 (55) 42.3 (58) 14.6 (20) 2.2 (3) 0.7 (1) 4 (4–5) 
Pharmacist prescribing helps 
patients avoid physician 
follow-up 
21.2 (29) 30.7 (42) 27.7 (38) 12.4 (17) 8 (11) 4 (3–4) 
Pharmacists’ prescribing reduces 
prescribing errors 33.6 (46) 29.9 (41) 28.5 (39) 5.8 (8) 2.2 (3) 4 (3–5) 
Pharmacists’ prescribing will 
increase the quality of care for 
patients 
38.7 (53) 37.9 (52) 19.7 (27) 2.2 (3) 1.5 (2) 4 (4–5) 
Pharmacist prescribing increases 
pharmacists professional 
responsibility 
49.6 (68) 39.4 (54) 7.3 (10) 2.2 (3) 1.5 (2) 5 (4–5) 
Prescribing increases 
pharmacist’s workload 29.2 (40) 40.9 (56) 22.6 (31) 5.8 (8) 1.5 (2) 4 (3–5) 
Prescribing increases 
pharmacist’s job satisfaction 37.9 (52) 43.1 (59) 11.7 (16) 5.1 (7) 2.2 (3) 4 (4–5) 
Pharmacists’ prescribing allow 
greater utilization of 
pharmacist’s skills and 
experience 
46.7 (64) 37.9 (52) 11 (15) 2.9 (4) 1.5 (2) 4 (4–5) 
* 1 = ’’Strongly disagree’’, 5 = ’’Strongly agree’’. 
3.4. Perceived Barriers to Pharmacist Prescribing 
Several key themes emerged from participants’ responses, reflecting views about the need for 
legislation, concerns about pharmacist training and competency, support from doctors, existing 
healthcare practice cultures, and sufficient resources to fund pharmacist prescribing. These are now 
considered in turn: 
(a) Legislation—Lack of prescribing legislation for pharmacists and specifically at a national level 
was a frequently cited barrier that was perceived to prevent pharmacist prescribing in KSA (Box 1). 
Box 1. Legislation 
“There is NO national legislation that supports pharmacists prescribing” 
“Lack of national legislations to back up and protect pharmacists” 
“Lack of cooperation between government and institutions to make sure that pharmacists are well 
oriented to prescribe” 
(b) Pharmacists training and competency—participants highlighted the issue of lack of 
appropriate training that would enable pharmacists to prescribe, both in terms of competency 
but also as a qualification. There was an emphasis on the need for specified training programs 
in therapeutic areas along with national certification before granting pharmacists prescriptive 
authorities (Box 2). 
Box 2. Pharmacists training and competency 
“I think the one important thing to achieve that level is to have qualified pharmacists who have 
enough experience to minimize the risk of prescribing mistakes” 
“[…] need specified training, in each specialty…. and need condensed courses and programs to 
improve pharmacist’s knowledge and practice” 
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“Still need time and more practice” 
“Need appropriate training and national competency certification” 
(c) Physicians’ perceived negativity—most participants believed that there was significant 
resistance from physicians, which represented a key barrier to implementing any form of 
pharmacist prescribing practice in KSA (Box 3). This appeared to be related to aspects such as 
physicians’ lack of awareness of pharmacists and not wanting to work in an inter-disciplinary 
way. 
Box 3. Physicians’ perceived negativity 
“Lack of physicians’ support and collaboration” 
“Physicians are not aware of the extent of pharmacists knowledge and abilities” 
“Doctors don’t like pharmacist to intervene in their job” 
“This idea is not accepted by multidisciplinary teams” 
“Physicians resistance only, as patients do trust pharmacists and ask them for advice about their 
medical conditions” 
(d) Healthcare practice culture—many participants believed that there were certain norms within 
healthcare practice in KSA that represents a barrier to extending pharmacist role to a prescriber. 
Many respondents referred to how patients are used to seeking medical care only from 
physicians and that patients view pharmacists only as a dispenser of medications who are not 
involved in patients’ care (Box 4). 
Box 4. Healthcare practice culture 
“The patient trusts the physician more than pharmacist” 
“Expectations from patients and other healthcare providers” 
“For many years prescribing medications was limited to medical doctors” 
“The nature of how things are processed in the hospital…each person has a specific role” 
(e) Limited resources—participants also suggested that there are limitations in resources that 
could facilitate the adoption of pharmacists’ prescribing in KSA. In this context, participants 
mentioned that pharmacists do not have enough time to practice as prescribers giving their 
workload and the demanding nature of their traditional roles as pharmacists. In addition, they 
mentioned that pharmacists do not have full access to patient’s information to allow them to 
practice as prescribers (Box 5). 
Box 5. Limited resources 
“No enough time to practice as prescribers” 
“Pharmacists workload” 
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“The pharmacists are not allowed to get full information about patient case and are not trusted by 
patients or physicians”  
3.5. Pharmacist Prescribing Practice 
Just over a quarter of pharmacists (28.5%, n = 39) described themselves as prescribers (Table 3). 
From this subgroup of prescribing respondents just under half (48.7%, n = 19) described their 
prescribing as collaborative, in which they initiated and monitored medicines according to a CMP 
that has been agreed in conjunction with a physician. In contrast, only 18% (n = 7) followed an 
independent prescribing model, in which they are responsible for assessing patients and making 
decisions about their CMP including prescribing medications. The remaining third (33.3%, n = 13) 
reported prescribing using both independent and collaborative prescribing models. When asked 
about the source of their prescribing authority, around half of prescribing pharmacists (51.3%, n = 
20) cited both a collaborative agreement with a medical team as well as approval by their institution 
as being needed to prescribe; around a third (30.7%, n = 12) reported a collaborative agreement with 
a medical team only, and the remaining 18% (n = 7) of pharmacists were granted the authority to 
prescribe by their institution only (Table 3). More than half of prescribing pharmacists (53.8%, n = 21) 
have received training in prescribing and the majority had access to patients’ medical records during 
prescribing (82%, n = 32). The median number of prescriptions that were prescribed by pharmacists 
in a typical week was reported to be 10 (IQR = 5–35), and it involved spending a median of 15 min to 
complete a prescription (IQR = 5–20) (Table 3). 
The most reported prescribing activities (59%, n = 23) involved dose and frequency adjustments, 
followed by renal dose adjustments and therapeutic drug monitoring (TDM) (53.8%, n = 21) (Figure 
1). The most prescribed medications by respondents (Figure 2) were anticoagulants (53.8%, n = 21), 
followed by parenteral nutrition and antimicrobials reported by (41%, n = 16) and (33.3%, n = 13) of 
participants, respectively. 
Table 3. Responses from prescribing pharmacists (n = 39). 
Questions % (n) 
Type of prescribing model practiced by the 
pharmacist 
Independent prescribing 18 (7) 
Collaborative prescribing 48.7 (19) 
Both independent and collaborative prescribing 33.3 (13) 
Prescriptive authority was given to the pharmacist 
by… 
The institution he/she work in 18 (7) 
A collaborative agreement with the medical team 30.7 (12) 
A collaborative agreement with a medical team that was 
approved by the administration of the institution 
51.3 (20) 
Prescribing training received (other than 
postgraduate clinical training or qualification) 
Yes 53.8 (21) 
No 46.2 (18) 
Access to patients’ medical records during 
prescribing 
Yes 82 (32) 
No 18 (7) 
As a result of pharmacists’ prescribing, doctors are 
prescribing … 
less 41 (16) 
more  35.9 (14) 
The same amount 23.1 (9) 
Time spent (in minutes) to complete a prescription including documentation in patients’ records 15 (5–20) * 
Prescriptions issued by pharmacists per week 10 (5–35) * 
* Median (IQR). 
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Figure 1. Domains of prescribing practice (n = 39). 
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3.6. Experience of Prescribing Pharmacists 
Table 4 summaries participants’ (n = 39) responses to statements on their prescribing 
experience. Most respondents were confident to prescribe in their area of practice (89.7%, n = 35) and 
believed that prescribing makes their job more satisfying (87.2%, n = 34). Results showed a positive 
correlation between the age of respondents and their level of confidence to prescribe (r = 0.329, p = 
0.041). No such correlation was identified with respondent’s experience or their highest 
professional/academic qualifications (r = 0.205, p = 0.212; r = 0.142, p = 0.389, respectively). 
Respondents expressed awareness of their limitations as prescribers (92.3%, n = 36) and perceived 
that more training would benefit them as prescribers (92.3%, n = 36). Most of the participants agreed 
that prescribing increased their workload (74.4%, n = 29), and they also expressed satisfaction at the 
level of training they completed before prescribing (74.4%, n = 29), and support received from the 
medical teams (76.9%, n = 30) or the institution (66.7%, n = 26). Participants were asked about their 
preferences for prescribing practice and 38.6% (n = 15) agreed that both collaborative agreement with 
physicians and also independent prescribing in their area of expertise were preferable; a further 
38.6% (n = 15) agreed with collaborative prescribing only and were either neutral or negative about 
independent prescribing, and only 17.9% (n = 7) agreed with independent prescribing but were 
neutral or negative about collaborative practice; 5.1% (n = 2) were neutral about both practices. 
Additionally, (35.9%, n = 14) of participants faced resistance from physicians or other healthcare 
professionals during their prescribing practice. A negative correlation was identified between the 
resistance participants have faced from physicians or other healthcare providers during their 
prescribing practice and their highest professional/academic qualifications (r = −0.393, p = 0.013). No 
correlation was identified with respondent’s experience or their age (r = 0.155, p = 0.347; r = −0.167, p 
= 0.310). 
Table 4. The opinion of pharmacists on their prescribing experience (n = 39). 
Statements 
Responses *, % (n) 
Strongly 





I am confident to prescribe the 
appropriate treatment for patients in 
my practice area 
51.2 (20) 38.5 (15) 5.1 (2) 2.6 (1) 2.6 (1) 5 (4–5) 
Being a prescriber makes my job 
more satisfying 
46.2 (18) 41 (16) 10.2 (4) 2.6 (1) 0 4 (4–5) 
I am aware of my limitations as a 
prescriber 
53.8 (21) 38.5 (15) 7.7 (3) 0 0 5 (4–5) 
Prescribing has increased my 
workload 
35.9 (14) 38.5 (15) 12.8 (5) 5.1 (2) 7.7 (3) 4 (3–5) 
I am satisfied by the level of training I 
received before prescribing 
41 (16) 33.3 (13) 12.8 (5) 7.7 (3) 5.1 (2) 4 (3–5) 
The medical team I work with are 
cooperative and supportive to my 
prescribing practice 
48.7 (19) 28.2 (11) 12.8 (5) 7.7 (3) 2.6 (1) 4 (4–5) 
I faced resistance from physicians or 
other healthcare professionals during 
my prescribing practice 
12.8 (5) 23.1 (9) 28.2 (11) 23.1 (9) 12.8 (5) 3 (2–4) 
My institution had been supportive 
of pharmacist prescribing 
30.8 (12) 35.9 (14) 25.6 (10) 5.1 (2) 2.6 (1) 4 (3–5) 
I prefer to prescribe only within a 
collaborative agreement with 
physicians 
38.5 (15) 38.5 (15) 15.3 (6) 7.7 (3) 0 4 (4–5) 
I prefer to practice as an independent 
prescriber in my area of expertise 
25.6 (10) 30.8 (12) 25.6 (10) 10.3 (4) 7.7 (3) 4 (3–5) 
Receiving more training in 
prescribing will benefit me as a 
prescriber 
69.2 (27) 23.1 (9) 7.7 (3) 0 0 4 (4–5) 
* 1 = ’’Strongly disagree’’, 5 = ’’Strongly agree’’. 
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3.7. Comparison between Prescribing and Non-prescribing Pharmacists 
Prescribing and non-prescribing pharmacists were compared in relation to key demographics. 
(Table 5). Prescribers were more likely to have a Pharm.D degree (p = 0.003), completed residency 
training (p = 0.001), and practice in clinical rather than a non-clinical pharmacy setting (p = 0.001). 
However, there was no significant difference identified in the gender between the two groups (p = 
0.849) or the type of healthcare institutions participants work in (p = 0.663). Additionally, both 
prescribing and non-prescribing pharmacists were from similar age groups (p = 0.305), had similar 
years of practice (p = 0.466), monthly income (p = 0.269), and average working hours in a typical 
week (p = 0.141). 
Table 5. Comparison between the characteristics of prescribing and non-prescribing pharmacists. 
Characteristics 
Prescribing Pharmacists 
(n = 39) % (n)  
Non-Prescribing Pharmacists 
(n = 98) % (n)  
p-Value 
Gender    
Male 46.2 (18) 48 (47) 
0.849 
Female 53.8 (21) 52 (51) 
Age group    
20–29 years 35.9 (14) 46.9 (46) 
0.583 
30–39 years 46.2 (18) 36.7 (36) 
40–49 years 12.8 (5) 13.3 (13) 
>50 years 5.1 (2) 3.1 (3) 
Doctor of pharmacy degree    
Yes 84.6 (33) 56.1 (55) 
0.003 
No 15.4 (6) 43.9 (43) 
Complete pharmacy 
residency 
   
Yes 59 (23) 9.3 (9) 
0.001 
No 41 (16) 90.7 (88) 
Healthcare institution    
Governmental 79.5 (31) 75.5 (74) 
0.663 
Private 20.5 (8) 24.5 (24) 
Practice setting    
Clinical pharmacy 61.5 (24) 25.5 (25) 
0.001 
Non-clinical 38.5 (15) 74.5 (73) 
Years of practice    
<5 years 41 (16) 50 (49) 
0.466 
6 to 10 years 31 (12) 21.4 (21) 
11 to 15 years 10 (4) 10.2 (10) 
16 to 20 years 8 (3) 13.3 (13) 
21 to 25 years 5 (2) 4.1 (4) 
>25 years 5 (2) 1 (1) 
Monthly income $    
<SR 10,000 15.4 (6) 11.2 (11) 
0.269 
SR 10,000–SR 20,000 67 (26) 66.3 (65) 
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SR 20,000–SR 30,000 5.1 (2) 11.2 (11) 
SR 30,000–SR 40,000 3 (1) 7.1 (7) 
>SR 40,000 8 (3) 1 (1) 
Average working hours in a 
typical week 
47.3 (23) * 44 (6.2) 0.141 
$ Responses may not add to 100% because of 4 missing responses. * Mean (SD). 
4. Discussion 
This study aimed to describe the informal pharmacist prescribing practices in Saudi Arabia, and 
the perceptions of hospital pharmacists on extending the role of pharmacists to that of prescribers. 
Results revealed that hospital pharmacists hold a positive attitude toward introducing legislation to 
support pharmacist prescribing formally and nationally in KSA and feel that prescribing would 
better utilize pharmacist’s skills and experience. Just over a quarter of participants identified 
themselves as current prescribing pharmacists and were mainly practicing in clinical pharmacy 
settings with collaborative practice agreements with physicians. Of note was that around half of 
prescribing pharmacists were practicing as independent prescribers. However, participants 
identified limited resources and healthcare practice culture as commonly perceived barriers to 
formalize this practice and introduce legislation to support it. 
Awareness was divided over the current lack of national legislation to support pharmacists’ 
prescribing in KSA. Although, pharmacy schools in KSA provide courses for pharmacy practice 
regulations as part of the curriculum [23], these findings reflect the limitations in pharmacist’s 
awareness of the MOH health practice regulations. Furthermore, participants expressed more 
agreement with limiting pharmacists’ prescribing to competent clinical pharmacists (65%), rather 
than allowing pharmacists, in general, to prescribe (38%). This may be related to clinical pharmacists 
in KSA having completed residency training programs that equipped them with advanced clinical 
skills and knowledge, allowing them to serve as direct patient-care providers [24,25]. In light of this, 
in the recent review by Al-Omi et al., pharmacist prescribing was declared as a new initiative in 
KSA, and as a new project it requires special training and education including clinical pharmacists, 
dispensing pharmacists, and technicians as well [26]. 
Results also showed that more than half of participants believed that pharmacists’ prescribing 
improved the quality of care for patients, reduced prescribing errors, and helped patients avoid 
physician’s follow-up. According to earlier studies that evaluated the outcomes of pharmacist’s 
medication therapy management compared to traditional medical care, when pharmacists managed 
drug-therapy initiation and monitoring, this resulted in patient outcomes equal and sometimes 
superior to those of standard care [12,27]. Additionally, pharmacists’ prescribing was perceived to 
reduce doctors’ workload in this study, which has also been reported in previous research involving 
the positive views of policymakers [28–30], doctors [31], and pharmacists [32]. This has benefits in 
terms of physicians having more time to deal with more complex cases, leaving more routine or 
pre-diagnosed patients to the care of prescribing pharmacist. 
More negatively, participants identified limitations in existing training and national 
certification programs and felt that these were not appropriate to allow pharmacists to become 
prescribers; physicians were also not felt to be supportive of pharmacists’ prescribing as they are 
unaware of pharmacist’s abilities and knowledge. Moreover, respondents perceived that the 
demanding nature of the pharmacist profession to represent a barrier for pharmacists to adopt a 
prescribing role. These finding are similar to previous research in which lack of time for pharmacists 
to take additional workload was identified as a barrier for pharmacist prescribing [33–36], along 
with limited support from physicians [31,37,38]. Similar negativity emerged in some aspects of the 
findings by Abdel-Latif [38], who sampled doctors in Saudi Arabia and identified a lack of 
awareness and willingness to accept advice on prescription changes. 
In relation to current self-reported prescribing practice and models, this study suggests that 
collaborative prescribing is the most common, either with local authority or combined with 
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independent prescribing. Those reporting only independent prescribing reflected 18% of 
prescribers. Evidence in the literature makes comparisons difficult and relatively little research have 
quantified the proportion of different NMP, which may be related to definitional issues and also 
different settings and practitioners [39]. One study in the US used an analysis of state legislation and 
identified a continuum and noted that categories of pharmacy NMP were not mutually exclusive 
and that collaborative prescribing guidelines were more common [40]. Given the infancy of NMP in 
KSA, the identification of more collaborative prescribing may reflect findings in other research 
where such prescribing—for example supplementary prescribing—might be more suited to those 
without previous experience as a “stepping stone” [41]. 
Pharmacists in this study were more commonly involved in prescribing for anticoagulants, 
parenteral nutrition, and infectious diseases or antimicrobials, which included prescribing activities 
like TDM and dose adjustments. The scope of this prescribing practice is similar to that in the USA, 
where most hospitals with established collaborative prescribing by pharmacists, allowed 
pharmacists to adjust drug strengths, order lab tests, and modify drug’s frequency for treatment 
areas similar to the ones in our study findings [12]. Moreover, in the USA within hospital settings 
pharmacists are authorized to adjust heparin infusions, and provide outpatient pain management, 
including prescribing of supplementary therapy such as antihistamines, laxatives, benzodiazepines 
and antiemetics [42]. In primary care settings in the UK, pharmacists with supplementary 
prescribing authority where mainly involved in clinical areas like hypertension, coronary heart 
disease, and diabetes. As for secondary care settings, TPN was identified as the specialty with the 
highest number of supplementary prescribers, and more pharmacists are being trained to prescribe 
in areas such as HIV, cystic fibrosis, and surgery/orthopedics [43]. 
Confidence in prescribing was positively correlated with pharmacists’ age, which may be 
related to the amount of experience gained by older pharmacists over time, and that increased 
confidence comes with increased age. Results also identified a negative correlation between 
physicians’ perceived resistance to pharmacists’ prescribing and the highest qualification for the 
prescribing pharmacist, indicating less resistance from physicians to prescribing pharmacists who 
are holding higher qualifications. Earlier research had highlighted the confidence factor in 
pharmacists’ prescribing practice. It was reported that confidence in prescribing comes from a 
defined area of competence [44], and that non-medical prescribers are cautious when prescribing but 
their confidence improves with good support from physicians [45,46]. Moreover, the majority of 
respondents (87%) agreed that prescribing did make their job more satisfying. This is also consistent 
with evidence from previous studies exploring pharmacists’ views on the impact of pharmacists’ 
prescribing, in which many pharmacists believed that prescribing would increase their job 
satisfaction [36,44–47]. 
4.1. Strengths and Limitations 
This is the first study to explore NMP attitudes and practices in KSA and using a quantitative 
survey design has revealed unique insights into pharmacists’ beliefs and current prescribing 
practice. Limitations in the study relate to the use of a self-report questionnaire, and respondents 
could have been self-selected with a greater interest in the study topic and, therefore, pharmacist’s 
prescribing results might not be specifically reflective of other—particularly non-prescribing 
pharmacists. The overall response rate to this survey was 14.8%, which is lower than some other 
studies using surveys with pharmacists [32,35]. Although participants were told not to complete the 
survey more than once, some of the pharmacists invited to participate from the 14 hospitals 
institutions could also have been invited as members of the professional organizations, caution is 
needed in generalizing from these findings to all pharmacists in KSA in the hospital setting. 
Additionally, assessing for non-response bias was not possible since information on pharmacists 
who did not respond was not available to the investigator in order to assess the likelihood of 
non-response bias by comparing the characteristics of responders and non-responders. 
  
Pharmacy 2020, 8, 160 15 of 18 
 
4.2. Implications for Policy, Practice and Future Research 
In articulating hospital pharmacists’ views and current local and informal practices, this study 
adds weight to claims that pharmacist’s prescribing in KSA should be legitimated through the 
introduction of national legislation. An implication of this is that hospitals should then adopt 
national prescribing arrangements rather than institutional ones. A further implication is that 
national legislation would standardize requirements needed for pharmacists to undertake 
prescribing. This could be in the form of pharmacist’s completion of prescribing training similar to 
the training requirements that is being implemented in developed countries, in which pharmacists 
are required to achieve a certain level of prescribing competency and pass tests to enable them to act 
as prescribers [48–50]. Finally, research is required to explore the views and opinions of stakeholders 
including not only pharmacists but also physicians and other healthcare professionals who are 
involved in patient care and prescribing to reflect their views on pharmacist’s prescribing, and also 
to evaluate the impact of pharmacists’ prescribing, on the quality of patient care, healthcare costs, 
and patient’s satisfaction. 
5. Conclusions 
There is an overall support for pharmacist prescribing in Saudi Arabia among this sample of 
hospital pharmacists. There is a general agreement by pharmacists for the need of specific 
prescribing training before allowing pharmacists to prescribe and national legislation to legitimize 
and standardize practice. Just over a quarter of respondent pharmacists were practicing as 
prescribers. Informal pharmacists’ prescribing activities were identified mainly within a 
collaborative practice agreement with physicians and practiced mainly by clinical pharmacists. Most 
of prescribing pharmacists were authorized to perform dose and frequency adjustments and TDM, 
and they were most frequently involved in prescribing activities for anticoagulants, parenteral 
nutrition, and antimicrobials. A key demographic difference between prescribing and 
non-prescribing pharmacists in KSA was the completion of residency training and practice in a 
clinical pharmacy setting. In general, there is support from tertiary care hospitals to pharmacists’ 
prescribing, and collaborative practice agreements are approved by hospital administrations in most 
cases. Healthcare practice culture and limitations in the availability of standardized prescribing 
training are key barriers to the legislation of pharmacists’ prescribing in Saudi Arabia. 
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